These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biological agents in kidney transplantation: belatacept is entering the field. Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688 [TBL] [Abstract][Full Text] [Related]
5. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478 [TBL] [Abstract][Full Text] [Related]
7. Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplant. Reynolds BC; Talbot D; Baines L; Brown A Pediatr Transplant; 2014 Aug; 18(5):E140-5. PubMed ID: 24815506 [TBL] [Abstract][Full Text] [Related]
8. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Fortin MC; Raymond MA; Madore F; Fugère JA; Pâquet M; St-Louis G; Hébert MJ Am J Transplant; 2004 Jun; 4(6):946-52. PubMed ID: 15147429 [TBL] [Abstract][Full Text] [Related]
9. [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period]. Gutiérrez de la Fuente C; Sola E; Alférez MJ; Navarro A; Cabello M; Burgos D; González Molina M Nefrologia; 2004; 24 Suppl 3():3-6. PubMed ID: 15219059 [TBL] [Abstract][Full Text] [Related]
11. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295 [TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431 [TBL] [Abstract][Full Text] [Related]
13. Rationale for using belatacept in combination with sirolimus. Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656 [TBL] [Abstract][Full Text] [Related]
15. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Barone GW; Gurley BJ; Abul-Ezz SR; Gökden N Am J Kidney Dis; 2003 Jul; 42(1):202-6. PubMed ID: 12830473 [TBL] [Abstract][Full Text] [Related]
16. Belatacept: a new biologic and its role in kidney transplantation. Su VC; Harrison J; Rogers C; Ensom MH Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686 [TBL] [Abstract][Full Text] [Related]
17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Martin ST; Powell JT; Patel M; Tsapepas D Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007 [TBL] [Abstract][Full Text] [Related]
18. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Martin ST; Tichy EM; Gabardi S Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628 [TBL] [Abstract][Full Text] [Related]
19. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Klintmalm GB; Feng S; Lake JR; Vargas HE; Wekerle T; Agnes S; Brown KA; Nashan B; Rostaing L; Meadows-Shropshire S; Agarwal M; Harler MB; Garcia-Valdecasas JC Am J Transplant; 2014 Aug; 14(8):1817-27. PubMed ID: 25041339 [TBL] [Abstract][Full Text] [Related]
20. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Pellé G; Xu Y; Khoury N; Mougenot B; Rondeau E Am J Kidney Dis; 2005 Dec; 46(6):1124-8. PubMed ID: 16310579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]